Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology
Background Atopic dermatitis (AD) is the most common inflammatory disease. Evolving
disease models link changes in epidermal growth and differentiation to TH 2/TH 22 cytokine
activation. However, these models have not been tested by in vivo suppression of T-cell
cytokines. Cyclosporine (CsA) is an immunosuppressant that is highly effective for severe
disease, but its mechanism in AD skin lesions has not been studied. Objective We sought to
establish the ability of a systemic immunosuppressant to modulate immune and epidermal …
disease models link changes in epidermal growth and differentiation to TH 2/TH 22 cytokine
activation. However, these models have not been tested by in vivo suppression of T-cell
cytokines. Cyclosporine (CsA) is an immunosuppressant that is highly effective for severe
disease, but its mechanism in AD skin lesions has not been studied. Objective We sought to
establish the ability of a systemic immunosuppressant to modulate immune and epidermal …